Cannabinoid Encyclopedia

Focused research review

CB1 receptor pharmacology: what the research says

What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?

Updated July 2026 33 research sources Mostly early-stage research

The short answer

What is the bottom line?

Research has examined CB1 receptor pharmacology. This page brings together 7 human-study sources, 15 research reviews, and 11 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CB1 receptor pharmacology.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on CB1 receptor pharmacology covers CB1; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about CB1 receptor pharmacology

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

CB1

This part of the literature focuses on CB1. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

15 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

11 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CB1 receptor pharmacology is not one kind of study. This source set includes 15 narrative or expert reviews, 9 animal studies, and 3 cell or laboratory studies. 3

The recorded populations or models include people or patients (8 sources), cells or tissue models (7 sources), and animal models (5 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is cB1 receptor pharmacology, ligand binding, or signaling mechanisms (33 sources). Closely related outcome names can still describe different measurements. 5

The CB1 receptor pharmacology source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

On this page, this source examines Endocannabinoids activity involving CB1. 1

Study type
narrative or expert review
Outcome focus
cB1 receptor pharmacology, ligand binding, or signaling mechanisms
Evidence stage
evidence still limited

mechanism-focused research

Crystal structures of agonist-bound human cannabinoid receptor CB1.

On this page, this source examines HHC activity involving CB1. 2

Population or model
people or patients
Outcome focus
cB1 receptor pharmacology, ligand binding, or signaling mechanisms
Evidence stage
mechanism-focused research

cell or laboratory study

Oxa-adamantyl cannabinoids.

On this page, this source examines Cannabinoids activity involving CB1. 3

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
cB1 receptor pharmacology, ligand binding, or signaling mechanisms
Evidence stage
evidence still limited

narrative or expert review

Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.

On this page, this source examines Cannabinoids activity involving CB1. 4

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
cB1 receptor pharmacology, ligand binding, or signaling mechanisms
Evidence stage
evidence still limited

narrative or expert review

Cannabinergic ligands.

On this page, this source examines Endocannabinoids activity involving CB1. 5

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
cB1 receptor pharmacology, ligand binding, or signaling mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CB1 receptor pharmacology should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?

Relevant research is collected here. Most of the current evidence is preclinical or focused on biological mechanisms. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. narrative or expert review; evidence still limited PubMed 27879006 DOI 10.1002/med.21418
  2. 2
    Crystal structures of agonist-bound human cannabinoid receptor CB1. mechanism-focused research PubMed 40866700 DOI 10.1038/s41586-025-09454-5
  3. 3
    Oxa-adamantyl cannabinoids. cell or laboratory study; evidence still limited PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
  4. 4
    Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. narrative or expert review; evidence still limited PubMed 29355030 DOI 10.1080/03602532.2018.1428342
  5. 5
    Cannabinergic ligands. narrative or expert review; evidence still limited PubMed 12505686 DOI 10.1016/s0009-3084(02
  6. 6
    Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. narrative or expert review; evidence still limited PubMed 18537620 DOI 10.2174/092986708784567716
  7. 7
    Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery. narrative or expert review; evidence still limited PubMed 39828030 DOI 10.1016/j.pharmthera.2025.108795
  8. 8
    CB1 Cannabinoid Receptor Signaling and Biased Signaling. narrative or expert review; evidence still limited PubMed 34500853 DOI 10.3390/molecules26175413
  9. 9
    Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist. narrative or expert review; evidence still limited PubMed 31490743 DOI 10.2174/0929867326666190906155339
  10. 10
    Endocannabinoids and Their Pharmacological Actions. narrative or expert review; evidence still limited PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
  11. 11
    Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. narrative or expert review; evidence still limited PubMed 28527758 DOI 10.1016/j.neuropharm.2017.05.018
  12. 12
    Pharmacological actions of cannabinoids. narrative or expert review; evidence still limited PubMed 16596770 DOI 10.1007/3-540-26573-2_1
See all 33 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Oxa-adamantyl cannabinoids. cell or laboratory study; evidence still limited / 1 linked research note PubMed 33636308
  2. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. narrative or expert review; evidence still limited / 1 linked research note PubMed 18537620
  3. Pharmacological actions of cannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 16596770
  4. Crystal structures of agonist-bound human cannabinoid receptor CB1. mechanism-focused research / 1 linked research note PubMed 40866700
  5. Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. animal study; mechanism-focused research / 1 linked research note PubMed 35489334
  6. Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. mechanism-focused research / 1 linked research note PubMed 38101408
  7. A cryptic pocket in CB1 drives peripheral and functional selectivity. animal study; mechanism-focused research / 1 linked research note PubMed 40044849
  8. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. narrative or expert review; evidence still limited / 1 linked research note PubMed 28527758
  9. Cannabinergic ligands. narrative or expert review; evidence still limited / 1 linked research note PubMed 12505686
  10. Assay of CB1 Receptor Binding. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 27245890
  11. Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1. animal study; mechanism-focused research / 1 linked research note PubMed 38830102
  12. Pharmacology of cannabinoid receptor ligands. narrative or expert review; evidence still limited / 1 linked research note PubMed 10469884
  13. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. narrative or expert review; evidence still limited / 1 linked research note PubMed 27879006
  14. The CB1 cannabinoid receptor in the brain. narrative or expert review; evidence still limited / 1 linked research note PubMed 9974174
  15. CB1 Cannabinoid Receptor Signaling and Biased Signaling. narrative or expert review; evidence still limited / 1 linked research note PubMed 34500853
  16. Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. narrative or expert review; evidence still limited / 1 linked research note PubMed 30333554
  17. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 22343625
  18. CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity. animal study; mechanism-focused research / 1 linked research note PubMed 38675703
  19. Allosteric modulation of the cannabinoid CB1 receptor. animal study; mechanism-focused research / 1 linked research note PubMed 16113085
  20. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. animal study; mechanism-focused research / 1 linked research note PubMed 31968549
  21. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. animal study; mechanism-focused research / 1 linked research note PubMed 28103441
  22. Endocannabinoids and Their Pharmacological Actions. narrative or expert review; evidence still limited / 1 linked research note PubMed 26408156
  23. The future of type 1 cannabinoid receptor allosteric ligands. mechanism-focused research / 1 linked research note PubMed 29355038
  24. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). mechanism-focused research / 1 linked research note PubMed 25162172
  25. Crystal structures of agonist-bound human cannabinoid receptor CB1. mechanism-focused research / 1 linked research note PubMed 28678776
  26. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. narrative or expert review; evidence still limited / 1 linked research note PubMed 29355030
  27. Synthetic Cannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 26132518
  28. Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery. narrative or expert review; evidence still limited / 1 linked research note PubMed 39828030
  29. Structural mechanism of CB1R binding to peripheral and biased inverse agonists. mechanism-focused research / 1 linked research note PubMed 39695122
  30. Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction. animal study; mechanism-focused research / 1 linked research note PubMed 41559687
  31. Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist. animal study; mechanism-focused research / 1 linked research note PubMed 40521518
  32. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. narrative or expert review; evidence still limited / 1 linked research note PubMed 33811300
  33. Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist. narrative or expert review; evidence still limited / 1 linked research note PubMed 31490743